15-Deoxy-γ12,14-prostaglandin J2 Reduces Liver Impairment in a Model of ConA-Induced Acute Hepatic Inflammation by Activation of PPARγ and Reduction in NF-κB Activity

Figure 2

Pretreatment with 15d-PGJ2 reduced the production of IL-2, IL-6, IL-12, and TNF-α in ConA-induced hepatitis. (a) The index of plasma IL-2, IL-6, IL-12, and TNF-α levels at 6 h, 12 h, and 24 h after ConA injection in mice and effects of both low (10 μg) and high (25 μg) dose 15d-PGJ2 pretreatment groups at the same time. Data are expressed as mean ± SD (𝑛=6, ^∗𝑃<0.05 for NC versus ConA, ^#𝑃<0.05 for ConA versus ConA + 10 μg 15d-PGJ2, and ⁺𝑃<0.05 for ConA versus ConA + 25 μg 15d-PGJ2). (b) The mRNA expression of IL-2, IL-6, IL-12, and TNF-α in NC, ConA, ConA + 10 μg 15d-PGJ2, and ConA + 25 μg 15d-PGJ2 group was evaluated by Real-Time PCR (𝑛=6, ^∗𝑃<0.05 for NC versus ConA, ^#𝑃<0.05 for ConA versus ConA + 10 μg 15d-PGJ2, and ⁺𝑃<0.05 for ConA versus ConA + 25 μg 15d-PGJ2).

(a)

(b)